Thomas Kislan
Optometrist · Stroudsburg, PANPI 1255319646
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $205,089 of the $266,378 with a category attached, or 77.0%. 39 manufacturers reported payments, led by AbbVie at 33.5% of the total. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 788 payments — averaging $338.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$89K
- Sun Pharmaceutical Industries Inc.$46K
- Bausch & Lomb Americas Inc.$39K
- Oyster Point Pharma, Inc.$23K
- Tarsus Pharmaceuticals, Inc.$21K
- Alcon$10K
- plus $39K from 33 others
Across 5 payments — averaging $977.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
What the payments were for
- Consulting fees$17,9757%
- Speaking & faculty fees$205,08977%
- Travel & lodging$21,6718%
- Food & beverage$21,5258%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$48,238
- CEQUA$44,329
- XIIDRA$32,791
- MIEBO$30,584
- TYRVAYA$22,572
- XDEMVY$20,630
- RESTASIS$17,973
- RESTASIS MULTIDOSE$14,328
- TRYPTYR$8,533
- LOTEMAX SM$8,471
- Rhopressa$4,204
- Rocklatan$4,204
- LUMIGAN$2,834
- Oxervate$2,487
- Lacrifill$2,450
- Eye Health$1,314
- TearCare$1,106
- Syfovre$1,065
- ALPHAGAN P$919
- COMBIGAN$800
How this compares
$266,378 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 25 | $1,351,285 |
| RestasisCyclosporine | 232 | $316,962 |
| LumiganBimatoprost | 187 | $112,000 |
| XiidraLifitegrast | 76 | $103,297 |
| MieboPerfluorohexyloctane/Pf | 93 | $77,329 |
| CequaCyclosporine | 61 | $72,362 |
| Cyclosporine | 78 | $55,828 |
| XdemvyLotilaner | 20 | $36,994 |
| Lotemax SmLoteprednol Etabonate | 100 | $36,185 |
| CombiganBrimonidine Tartrate/Timolol | 77 | $25,487 |
| TyrvayaVarenicline Tartrate | 20 | $22,079 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $21,195 |
| EysuvisLoteprednol Etabonate | 25 | $14,976 |
| VyzultaLatanoprostene Bunod | 50 | $14,586 |
| Alphagan PBrimonidine Tartrate | 24 | $7,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $2,827 | $1,351,28525 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $89,167 | $461,892520 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $38,526 | $195,212219 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $45,656 | $72,36261 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $21,434 | $36,99420 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $5,728 | $36,185100 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $23,355 | $22,07920 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $4,254 | $21,19539 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $224 | $14,97625 claims |
| Eyevance Pharmaceuticals LLCFlarex | $61 | $1,82715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in Stroudsburg
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Leslie O DellNew Freedom$388K
- Kevin BistlinePlymouth Meeting$302K
- Erick HendersonPittsburgh$266K
- Ryan YealyLancaster$164K
- Joseph SmayNew Kensington$147K
- Julie McLaughlinAllentown$142K
- Robert RosenthalNewtown$127K
- Michael CymborState College$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.